查看文章

Throughout the COVID-19 pandemic, the BNT162b2 (manufactured by Pfizer—BioNTech) and mRNA-1273 (manufactured by Moderna Inc) vaccines have demonstrated an acceptable safety profile and a high degree of effectiveness in preventing severe COVID-19 outcomes in healthy individuals. However, it remains to be determined if similar benefits can be replicated in immunocompromised patients, who were largely excluded from Phase III clinical trials. Preliminary data on vaccine immunogenicity among lupus patients reveal blunted humoral responses, particularly in those using prednisone and/or mycophenolate (1-2).

This study sought to measure the antibody responses following SARS-CoV-2 vaccination in patients with SLE and to identify clinical and laboratory parameters associated with low antibody responses.

We prospectively enrolled SLE patients from the Beth Israel …